Generex Biotechnology Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 11/21/2020)
| Balance Sheet | Total Assets | 45,382,900.00 | ROE | – |
| Balance Sheet | Total Equity | -21,456,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -4,616.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -6,125,876.00 | – | – |
| Cashflow | Operating Cash Flow | -6,121,260.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -0.46 | Div. Yield | – |
| Income | Net Income | -33,335,000.00 | P/E | – |
| Income | Shares Outstanding | 74,417,600.00 | P/B | – |
| Income | Total Revenue | 2,661,400.00 | P/S | – |
Ratios calculated on: –
Company Description
Generex Biotechnology Corporation is engaged in pharmaceutical and biotechnological research and development of drug delivery systems and technologies, and other activities. The Company offers a platform technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. It develops drug delivery systems and technologies for metabolic and immunological diseases. The Company is conducting pre-clinical and human clinical trials using its technology platforms in the areas of diabetes, pain management and cancers. Its buccal insulin product, Generex Oral-lyn, provides a needle-free means of delivering insulin for the patients suffering from type I diabetes and type II diabetes. Its buccal delivery technology involves the preparation of formulations in which an active pharmaceutical agent is placed in a solution with a combination of absorption enhancers and other excipients.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.generex.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more